| Yu, Shengyuan |
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | 4 | 1312 | RoW | GV-971, Placebo | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer's Disease | 06/29 | 12/29 | | |
BHV3000-318, NCT05371652: A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants |
|
|
| Completed | 3 | 241 | RoW | Rimegepant 75mg Orally Disintegrating Tablets (ODT) | Pfizer, Bioshin (Shanghai) Consulting Services Co., Ltd | Acute Migraine | 02/24 | 02/24 | | |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
| Wang, Ruimin |
NCT05814835: First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors |
|
|
| Completed | 1 | 14 | RoW | 2-4 mCi 68Ga/64Cu-FAPI-XT117, 4-6 mCi 68Ga/64Cu-FAPI-XT117, 6-8 mCi 68Ga/64Cu-FAPI-XT117 | Chinese PLA General Hospital, Sinotau Pharmaceutical Group | Malignant Solid Tumors | 11/23 | 12/23 | | |
NCT06211647: A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | [177Lu]Lu-XT117 | Ruimin Wang, Sinotau Pharmaceutical Group | Advanced Solid Tumor | 12/25 | 12/26 | | |
| shen, zhihui |
NCT05814835: First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors |
|
|
| Completed | 1 | 14 | RoW | 2-4 mCi 68Ga/64Cu-FAPI-XT117, 4-6 mCi 68Ga/64Cu-FAPI-XT117, 6-8 mCi 68Ga/64Cu-FAPI-XT117 | Chinese PLA General Hospital, Sinotau Pharmaceutical Group | Malignant Solid Tumors | 11/23 | 12/23 | | |
| Yin, Ang |
NCT06211647: A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | [177Lu]Lu-XT117 | Ruimin Wang, Sinotau Pharmaceutical Group | Advanced Solid Tumor | 12/25 | 12/26 | | |
